Carmen Criscitiello

List of Publications by Year
in descending order

99 papers	7,034 citations	109264 35 h-index	62565 80 g-index
100 all docs	100 docs citations	100 times ranked	10856 citing authors

#	Article	IF	Citations
1	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271.	0.6	2,122
2	Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology, 2012, 23, vii155-vii166.	0.6	667
3	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Ca-A Cancer Journal for Clinicians, 2016, 66, 309-325.	157.7	485
4	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Annals of Oncology, 2014, 25, 611-618.	0.6	359
5	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. Journal of Clinical Oncology, 2012, 30, 1996-2004.	0.8	194
6	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Npj Breast Cancer, 2020, 6, 54.	2.3	181
7	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologistsâ€™ perspective. ESMO Open, 2020, 5, e000759.	2.0	161
8	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology, 2019, 30, 1941-1949.	0.6	155
9	Antibodyâ€“drug conjugates in solid tumors: a look into novel targets. Journal of Hematology and Oncology, 2021, 14, 20.	6.9	129
10	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	1.1	100
11	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. Breast, 2014, 23, 69-75.	0.9	92
12	Evolution of low HER2 expression between early and advanced-stage breast cancer. European Journal of Cancer, 2022, 163, 35-43.	1.3	88
13	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast, 2017, 35, 142-150.	0.9	87
14	Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, 157, 120-124.		86
15	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 644737.	1.3	70
16	Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. Pharmaceuticals, 2014, 7, 943-953.	1.7	69
17	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, 11, 719.	1.0	67
18	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	1.6	63

#	Article	IF	Citations
19	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an â€œInnocent Bystanderâ€• Toxins, 2014, 6, 914-933.	1.5	62
20	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers, 2020, 12, 819.	1.7	61
21	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2â^' breast cancer. Breast Cancer Research and Treatment, 2020, 183, 347-354.	1.1	59
22	Tumor-Associated Antigens in Breast Cancer. Breast Care, 2012, 7, 262-266.	0.8	56
23	Entinostat for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 965-971.	1.9	54
24	The Emerging Role of â€œLiquid Biopsies,â€•Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Current Oncology Reports, 2017, 19, 1.	1.8	53
25	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2021, 159, 103223.	2.0	52
26	Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience, 2015, 9, 518.	0.6	50
27	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treatment Reviews, 2016, 50, 205-207.	3.4	50
28	Cardiotoxicity of systemic agents used in breast cancer. Breast, 2014, 23, 317-328.	0.9	49
29	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. Frontiers in Oncology, 2020, 10, 556718.	1.3	49
30	Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. Cancer Treatment Reviews, 2015, 41, 61-68.	3.4	48
31	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. European Journal of Cancer, 2019, 118, 41-48.	1.3	48
32	Circulating tumor cells and emerging blood biomarkers in breast cancer. Current Opinion in Oncology, 2010, 22, 552-558.	1.1	46
33	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology, 2018, 29, 162-169.	0.6	46
34	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	3.4	46
35	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Annals of Oncology, 2016, 27, 1860-1866.	0.6	45
36	Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy, 2014, 6, 349-360.	1.0	38

#	Article	IF	Citations
37	RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget, 2016, 7, 80901-80915.	0.8	37
38	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open, 2018, 3, e000368.	2.0	35
39	Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. European Journal of Cancer, 2018, 97, 1-6.	1.3	35
40	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. Cells, 2021, 10, 1377.	1.8	35
41	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Annals of Oncology, 2013, 24, 1980-1985.	0.6	32
42	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. Breast Cancer Research, 2019, 21, 123.	2.2	31
43	Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. European Journal of Surgical Oncology, 2015, 41, 1288-1292.	0.5	30
44	Immunotherapy of Breast Cancer. Progress in Tumor Research, 2015, 42, 30-43.	0.1	27
45	Mechanisms of anorexiaâ€“cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treatment Reviews, 2015, 41, 793-797.	3.4	27
46	Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?. European Journal of Surgical Oncology, 2016, 42, 1780-1786.	0.5	26
47	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy, 2021, 21, 945-962.	1.4	26
48	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
49	Targeted therapies in breast cancer: are heart and vessels also being targeted?. Breast Cancer Research, 2012, 14, 209.	2.2	24
50	Expression of tumor-associated antigens in breast cancer subtypes. Breast, 2020, 49, 202-209.	0.9	24
51	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0.784314 rgBT /Ov 1137.	1.7	22
52	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treatment Reviews, 2021, 97, 102205.	3.4	21
53	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers, 2022, 14, 2136.	1.7	21
54	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. BioMed Research International, 2015, 2015, 1-8.	0.9	20

#	Article	IF	Citations
55	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. International Journal of Surgery, 2016, 28, S172-S176.	1.1	20
56	Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. Breast, 2021, 57, 25-35.	0.9	20
57	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. Aging Clinical and Experimental Research, 2017, 29, 73-78.	1.4	19
58	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 829875.	1.3	19
59	Targeting fibroblast growth factor receptor pathway in breast cancer. Current Opinion in Oncology, 2015, 27, 452-456.	1.1	17
60	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581.	1.5	17
61	Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. Oncologist, 2020, 25, e1732-e1742.	1.9	16
62	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. European Journal of Cancer, 2021, 145, 197-209.	1.3	16
63	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. Breast Cancer: Targets and Therapy, 2018, Volume 10, 23-29.	1.0	15
64	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open, 2021, 6, 100104.	2.0	15
65	Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. Breast Cancer Research and Treatment, 2021, 187, 323-337.	1.1	15
66	Managing side effects of immune checkpoint inhibitors in breast cancer. Critical Reviews in Oncology/Hematology, 2021, 162, 103354.	2.0	15
67	A phase III trial of alpelisibÂ+Âtrastuzumab Â±Âfulvestrant versus trastuzumabÂ+ chemotherapy in HER2+ PIK3CA-mutated breast cancer. Future Oncology, 2022, 18, 2339-2349.	1.1	15
68	HER2 signaling pathway and trastuzumab cardiotoxicity. Future Oncology, 2013, 9, 179-181.	1.1	14
69	The use of breast imaging for predicting response toÂneoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: ResultsÂfrom Neo-ALTTO. European Journal of Cancer, 2018, 89, 42-48.	1.3	13
70	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. Cells, 2019, 8, 605.	1.8	12
71	Peptide vaccines in early breast cancer. Breast, 2019, 44, 128-134.	0.9	12
72	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. European Journal of Cancer, 2020, 139, 92-98.	1.3	12

#	Article	IF	Citations
73	No Link between Breast Cancer and Meningioma: Results from a Large Monoinstitutional Retrospective Analysis. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 215-217.	1.1	11
74	Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. Genes, 2021, 12, 253.	1.0	11
75	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histology and Histopathology, 2021, , 18376.	0.5	11
76	PIK3CA Mutation Assessment in HR+/HER2â^' Metastatic Breast Cancer: Overview for Oncology Clinical Practice. Journal of Molecular Pathology, 2021, 2, 42-54.	0.5	9
77	Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. Journal of the National Cancer Institute Monographs, 2015, 2015, 51-55.	0.9	8
78	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers, 2021, 13, 5829.	1.7	8
79	Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Annals of Oncology, 2014, 25, 910-911.	0.6	7
80	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. European Journal of Cancer, 2017, 87, 164-171.	1.3	7
81	Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO Open, 2021, 6, 100063.	2.0	7
82	Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. Cancer Treatment Reviews, 2021, 99, 102236.	3.4	7
83	Adjuvant treatment of early male breast cancer. Current Opinion in Oncology, 2020, 32, 594-602.	1.1	6
84	Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 299-305.	0.9	4
85	A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Review of Clinical Pharmacology, 2019, 12, 9-16.	1.3	4
86	Toward precision medicine in inflammatory breast cancer. Translational Cancer Research, 2019, 8, S469-S478.	0.4	4
87	How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. ESMO Open, 2022, 7, 100428.	2.0	4
88	Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. BioMed Research International, 2018, 2018, 1-2.	0.9	3
89	Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. Current Opinion in Oncology, 2019, 31, 472-479.	1.1	3
90	Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. European Journal of Cancer, 2020, 127, 236-239.	1.3	3

#	Article	IF	Citations
91	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. European Journal of Cancer, 2021, 157, 40-49.	1.3	3
92	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 832-836.	0.9	3
93	Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Current Opinion in Oncology, 2017, 29, 428-433.	1.1	2
94	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. European Journal of Cancer, 2019, 117, 1-4.	1.3	2
95	Incidental thyroid papillary microcarcinoma on 1777 surgically treated patients for benign thyroid disease. Memo - Magazine of European Medical Oncology, 2020, 13, 126-133.	0.3	1
96	ESMO Leaders Generation Programme: an alumni insight. ESMO Open, 2018, 3, e000312.	2.0	0
97	Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. Journal of Clinical Oncology, 2013, 31, 617-617.	0.8	0
98	Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.. Journal of Clinical Oncology, 2013, 31, 1595-1595.	0.8	0
99	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. Journal of Clinical Oncology, 2022, 40, 3063-3063.	0.8	0